Wave launches studies investigating two pipeline candidates in Huntington's disease; shares up 2%

|About: Wave Life Sciences (WVE)|By:, SA News Editor

Wave Life Sciences (WVE +1.8%) initiates two Phase 1b/2a studies, PRECISION-HD1 and PRECISION-HD2, assessing candidates WVE-120101 and WVE-120102, respectively, in patients with Huntington's disease (HD). The studies will assess the safety and tolerability of single and multiple doses of both administered directly into the spinal canal (intrathecally). Other exploratory objectives include assessing the impact of each antisense oligonucleotide on the toxic mutant protein that causes the loss of brain cells in HD sufferers.